Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Shanghai Fosun Pharmaceutical (Group) Co's Days Inventory for the
three
months ended in Mar. 2026 was 110.62.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Shanghai Fosun Pharmaceutical (Group) Co's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.82.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Shanghai Fosun Pharmaceutical (Group) Co's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.61.
Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Shanghai Fosun Pharmaceutical (Group) Co's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Shanghai Fosun Pharmaceutical (Group) Co's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Shanghai Fosun Pharmaceutical (Group) Co Total Inventories Related Terms
Shanghai Fosun Pharmaceutical (Group) Co Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co Total Inventories Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Shanghai Fosun Pharmaceutical (Group) Co Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) has a Total Inventories of ¥6,032 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Shanghai Fosun Pharmaceutical (Group) Co and its competitors.
Is Shanghai Fosun Pharmaceutical (Group) Co's Total Inventories too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Total Inventories is ¥6,032 Mil. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Total Inventories compare to ZTS?
Shanghai Fosun Pharmaceutical (Group) Co's Total Inventories of ¥6,032 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Shanghai Fosun Pharmaceutical (Group) Co and its competitors. Shanghai Fosun Pharmaceutical (Group) Co's current Total Inventories is ¥6,032 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥27.07, compared to a current price of ¥21.21 — trading 21.6% below its estimated fair value. The current Total Inventories is ¥6,032 Mil. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 76/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196), the current Total Inventories is ¥6,032 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued.
The current stock price of ¥21.21 is trading 21.6% below its estimated GF Value™ of ¥27.07.
GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:600196:
Total Inventories: ¥6,032 Mil
GF Value™: ¥27.07 vs. price of ¥21.21 (21.6% below fair value)
No single metric tells the full story. See the SHSE:600196 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fosun Pharmaceutical (Group) Co Business Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
76GF Score
Get the complete analysis for SHSE:600196
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600196 has been successfully added to your 
